News

# FDA, J&J set to announce Baltimore vaccine plant ready to reopen

Table of Contents

“#
FDA, J&J set to announce Baltimore vaccine plant ready to reopen
”

WASHINGTON — The Food and Drug Administration and vaccine maker Johnson & Johnson expect to announce as early as Friday that contamination problems at a COVID-19 vaccine plant in Baltimore are resolved, clearing the way for millions more doses to become available.

Vaccine production at the plant run by contract manufacturer Emergent BioSolutions Inc.
EBS,
+0.61%
was halted after unsanitary conditions led to contamination of J&J
JNJ,
-0.15%
vaccines. The facility made vaccine substance and finished vaccine doses for J&J and AstraZeneca
AZN,
+0.62%
PLC.

Emergent chief executive Robert Kramer told a House committee last week that the company had produced enough of a key ingredient to yield more than 100 million doses of the J&J vaccine.

The company has been taking corrective measures and been in talks with FDA and J&J over the steps needed to reopen the facility.

An expanded version of this report appears on WSJ.com.

Also popular on WSJ.com:

Why a grand plan to vaccinate the world against COVID unraveled.

The Texas grid came close to an even bigger disaster during February freeze.

Thomas M. Burton

If you liked the article, do not forget to share it with your friends. Follow us on Google News too, click on the star and choose us from your favorites.